News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for
Aflibercept in macular oedema after BRVO: No hint of added benefit
Source: Eye Health / Blindness News From Medical News Today [2015.06.24]
Dossier contained no suitable data, manufacturer itself claimed no added benefitSince February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due...
Patient-Reported Vision Improves After Ocriplasmin for Vitreomacular Adhesion
Source: Medscape Ophthalmology Headlines [2015.06.22]
Patients report meaningful improvements in vision after ocriplasmin treatment for vitreomacular adhesion (VMA), according to a pair of multicenter trials.
Reuters Health Information
Scripps team lays 'spectacular' foundations for HIV vaccine
Source: HIV / AIDS News From Medical News Today [2015.06.19]
Researchers at The Scripps Institute report preliminary success in designing a component for a potential HIV vaccine based on immunogens, rather than a deactivated virus.
NICE recommends EYLEA for visual impairment due to diabetic macular oedema (DMO)
Source: Eye Health / Blindness News From Medical News Today [2015.06.02]
The National Institute for Health and Care Excellence (NICE) draft Final Appraisal Determination (FAD) recommends EYLEA for the treatment of patients with visual impairment due to diabetic macular...
Source: MedicineNet Cataracts Specialty [2015.05.07]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 12:00:00 AM
Last Editorial Review: 5/7/2015 12:00:00 AM
Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.